FY 2023 Revenue of $172.4 Million; Income from Operations of $3.3 Million; Adjusted EBITDA of $53.4 Million or 31% of Revenue
Generated $12.2 Million of Operating Cash Flow in FY 2023
DENVER, March 27, 2024 /PRNewswire/ -- Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) ("Schwazze" or the "Company"), today announced financial and operational results for the fourth quarter and full year ended December 31, 2023.
"This past year, the Schwazze team delivered solid top-line growth in two highly competitive markets with 31% adjusted EBITDA margins and improved operating cash flow," said Forrest Hoffmaster, Interim CEO of Schwazze. "We continued to sharpen our retail strategy while expanding our store footprint by more than 50% to 63 dispensaries across our two markets. Although the Colorado and New Mexico markets were pressured in 2023, we have built a solid foundation with best-in-class service for our patients and customers. Internally, we are also relentlessly focused on maximizing the operating efficiencies of our manufacturing and cultivation facilities to drive higher yields, improved flower quality, and greater output."
"With strong demand and over 680 recreational retail stores at year-end, the competitive landscape in Colorado is fierce, underscoring the importance of our investments in and attention to elevating the customer experience. We significantly outpaced the market in Q4 on a sequential and year-over-year basis and expect to bolster our growth through improvements in customer acquisition, retention, and loyalty, as well as in the overall retail experience. Additionally, we are beginning to see wholesale pricing stabilize, which we anticipate will continue based on plant counts and ongoing retail pricing pressure."
"In New Mexico, the proliferation of new licenses has led to increased competition and aggressive pricing strategies from certain players. Cannabis sales in the state were up 18% across a store base that was over 50% higher year-over-year in Q4, leading to lower average revenue per store. While we are beginning to see a slow-down in net new store openings, we anticipate a challenging market ahead. We remain focused on cost optimization and asset utilization while implementing a balanced pricing and promotional strategy to drive traffic into our stores, where we believe we excel in delivering an elevated retail experience. We are committed to fulfilling our promise of being the retailer of choice in New Mexico."
"Looking ahead, we are optimistic about the regulatory momentum in the industry at large. In the meantime, we will continue to elevate the customer experience, improve our loyalty program, increase our cost efficiencies, and enhance our retail assets. Our team has a demonstrated track record of executing in competitive markets like Colorado and New Mexico where we remain one of the largest operators. We look forward to driving growth and profitability across each of our markets in 2024."
Fourth Quarter 2023 Financial Summary
$ in Thousands USD Q4 2023 Q3 2023 Q4 2022 Total Revenue $43,325 $46,747 $40,147 Gross Profit $7,034 $21,438 $21,719 Adjusted Gross Profit[1] $20,180 $21,438 $21,719 Operating Expenses $23,276 $12,514 $24,224 Income (Loss) from Operations $(16,242) $8,924 $(2,505) Adjusted EBITDA[2] $10,953 $14,119 $13,285 Operating Cash Flow $3,452 $6,946 $6,260
Full Year 2023 Financial Summary
$ in Thousands USD FY 2023 FY 2022 Total Revenue $172,448 $159,379 Gross Profit $76,024 $80,289 Adjusted Gross Profit1 $89,170 $86,830 Operating Expenses $72,735 $67,434 Income from Operations $3,289 $12,855 Adjusted EBITDA2 $53,412 $52,010 Operating Cash Flow $12,201 $6,694
___________________________ (1) Adjusted Gross Profit is a non-GAAP measure as defined by the SEC and represents gross profit excluding non-cash inventory adjustments. The Company uses Adjusted Gross Profit as it believes it better explains the results of its core business. See "ADJUSTED GROSS PROFIT RECONCILIATION (NON-GAAP)" section herein for an explanation and reconciliations of non-GAAP measure used throughout this release. (2) Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See "ADJUSTED EBITDA RECONCILIATION (NON-GAAP)" section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.
Full Year 2023 Operational Highlights
-- Expanded the Company's retail footprint by more than 50% in New Mexico
and Colorado to 63 dispensaries.
-- Completed the acquisition of Everest Apothecary, adding 14 dispensaries,
one cultivation facility, and one manufacturing plant to the Company's
New Mexico operations.
-- Acquired Standing Akimbo, the largest medical cannabis dispensary in
Colorado, and opened the Company's first medical dispensary in Colorado
Springs under the Standing Akimbo banner.
-- Acquired two Colorado retail dispensaries in Fort Collins and Garden
City from Smokey's.
-- Unveiled an enhanced, custom ecommerce platform in New Mexico under the
R. Greenleaf banner.
-- Increased wholesale penetration in Colorado and New Mexico by over 3x
year-over-year to more than 27% total door penetration in both states.
-- Grew Lowell Farms pre-roll sales by over 250% in Colorado where it is
now the #1 pre-roll in the state. In addition, Lowell is in six of the
largest Colorado accounts and will be available for wholesale in New
Mexico starting April 1(st), 2024.
-- Grew sales with Wana, our fan-favorite gummies brand, by 48% in New
Mexico where it is now in 130 doors with eight of the top ten accounts
in the state.
Fourth Quarter 2023 Financial Results
Total revenue in the fourth quarter of 2023 increased 8% to $43.3 million compared to $40.1 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period and increased wholesale revenue, partially offset by pricing pressure from the proliferation of new licenses in New Mexico.
Gross profit for the fourth quarter of 2023 was $7.0 million or 16.2% of total revenue, compared to $21.7 million or 54.1% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. Adjusted gross profit, which excludes non-cash inventory adjustments, for the fourth quarter of 2023 was $20.2 million or 46.6% of revenue.
Operating expenses for the fourth quarter of 2023 were $23.3 million compared to $24.2 million for the same quarter last year. The decrease was primarily due to a lower impairment charge in the fourth quarter of 2023. This was partially offset by an increase in four-wall SG&A expenses associated with the 22 additional stores in Colorado and New Mexico that are still ramping, as well as greater salaries and stock-based compensation.
Loss from operations for the fourth quarter of 2023 was $16.2 million compared to $2.5 million in the same quarter last year. The decrease was driven by the aforementioned lower gross profit, primarily related to the non-cash inventory adjustment. Net loss was $33.9 million for the fourth quarter of 2023 compared to $27.3 million for the same quarter last year.
Adjusted EBITDA for the fourth quarter of 2023 was $11.0 million or 25.3% of revenue, compared to $13.3 million or 33.1% of revenue for the same quarter last year. The decrease in Adjusted EBITDA margin was primarily driven by higher operating expenses associated with the 22 additional stores that are still ramping.
As of December 31, 2023, cash and cash equivalents were $19.2 million compared to $38.9 million on December 31, 2022. Total debt as of December 31, 2023, was $156.8 million compared to $127.8 million on December 31, 2022.
Conference Call
The Company will conduct a conference call today, March 27, 2024, at 5:00 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2023.
Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing ir@schwazze.com [mailto:ir@schwazze.com].
Date: Wednesday, March 27, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 38840334
Webcast: SHWZ Q4 & FY 2023 Earnings Call [https://c212.net/c/link/?t=0&l=en&o=4126675-1&h=3104431537&u=https%3A%2F%2Fapp.webinar.net%2FGDQNRZGPexA&a=SHWZ+Q4+%26+FY+2023+Earnings+Call]
The conference call will also be broadcast live and available for replay on the investor relations section of the Company's website at https://ir.schwazze.com [https://c212.net/c/link/?t=0&l=en&o=4126675-1&h=1584627286&u=https%3A%2F%2Fir.schwazze.com%2F&a=https%3A%2F%2Fir.schwazze.com].
Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 840334
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
Schwazze (OTCQX: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company's leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze's former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/ [https://c212.net/c/link/?t=0&l=en&o=4126675-1&h=2836062377&u=https%3A%2F%2Fschwazze.com%2F&a=https%3A%2F%2Fschwazze.com%2F].
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company's previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words "may," "will," "could," "would," "should," "expect," "intends," "plans," "strategy," "prospects," "anticipate," "believe," "approximately," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management's current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov [https://c212.net/c/link/?t=0&l=en&o=4126675-1&h=1102837779&u=http%3A%2F%2Fwww.sec.gov%2F&a=http%3A%2F%2Fwww.sec.gov]. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D'Souza
Elevate IR
(720) 330-2829
ir@schwazze.com [mailto:ir@schwazze.com]
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars
For the Three Months Ended For the Twelve Months Ended December 31, December 31, 2023 2022 2023 2022 (Unaudited) (Unaudited) (Audited) (Audited) Operating Revenues Retail $ 39,592,779 $ 36,868,429 $ 155,463,816 $ 141,254,893 Wholesale 3,730,749 3,158,670 16,765,425 17,819,938 Other 1,287 120,188 218,545 304,388 Total Revenue 43,324,815 40,147,287 172,447,786 159,379,219 Total Cost of Goods & Services 36,291,059 18,428,528 96,424,150 79,090,461 Gross Profit 7,033,756 21,718,759 76,023,636 80,288,758 Operating Expenses Selling, General and Administrative Expenses 10,848,029 8,922,627 39,916,518 29,036,962 Professional Services 1,115,457 1,112,975 3,558,501 6,722,554 Loss on Impairment 1,810,890 8,011,405 1,801,740 8,011,405 Salaries 6,561,800 5,292,996 23,883,354 20,990,290 Stock Based Compensation 2,952,669 883,890 3,574,831 2,672,713 Total Operating Expenses 23,288,845 24,223,893 72,734,944 67,433,924 Income from Operations (16,255,089) (2,505,134) 3,288,692 12,854,834 Other Income (Expense) Interest Expense, net (8,112,391) (6,827,557) (32,069,082) (30,139,645) Unrealized Gain (Loss) on Derivative Liabilities 1,384,228 (9,690,200) 15,870,233 18,414,760 Other Loss 68,400 3,736 68,400 24,136 Loss on Business Disposition (1,968,807) (4,684,366) (1,968,807) (4,684,366) Unrealized Gain (Loss) on Investments 3,083 1,816 (39,270) Total Other Income (Expense) (8,628,570) (21,195,304) (18,097,441) (16,424,385) Pre-Tax Net Income (Loss) (24,883,659) (23,700,438) (14,808,749) (3,569,551) Provision for Income Taxes 4,494,049 3,638,695 19,740,595 14,898,064 Net Income (Loss) $ (29,377,708) $ (27,339,133) $ (34,549,344) $ (18,467,615) Less: Accumulated Preferred Stock Dividends for the Period (1,541,341) (2,508,677) (8,154,993) (7,802,809) Net Income (Loss) Attributable to Common Stockholders $ (30,919,049) $ (29,847,810) $ (42,704,337) $ (26,270,424) Earnings (Loss) per Share Attributable to Common Stockholders Basic Earnings (Loss) per Share $ (0.43) $ (0.57) $ (0.66) $ (0.49) Diluted Earnings (Loss) per Share $ (0.43) $ (0.57) $ (0.66) $ (0.49) Weighted Average Number of Shares Outstanding - Basic 71,680,200 53,637,003 64,535,245 53,637,003 Weighted Average Number of Shares Outstanding - Diluted 71,680,200 53,637,003 64,535,245 53,637,003 Comprehensive Income (Loss) $ (29,377,708) $ (27,339,133) $ (34,549,344) $ (18,467,615)
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars
For the Twelve Months Ended December 31, 2023 2022 (Audited) (Audited) Cash Flows from Operating Activities: Net Income (Loss) for the Period $ (34,549,344) $ (18,467,615) Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities Depreciation & Amortization 20,933,541 10,660,172 Non-Cash Interest Expense 4,024,604 4,118,391 Impairment of Goodwill 1,801,740 8,011,405 Non-Cash Lease Expense 7,648,531 3,910,679 Deferred Taxes (2,090,967) 502,070 Loss on Disposition of Business Units 1,968,807 4,684,369 Change in Derivative Liabilities (15,870,233) (18,414,760) Amortization of Debt Issuance Costs 1,686,049 1,686,048 Amortization of Debt Discount 8,523,493 7,484,613 (Gain) Loss on Investments, net (1,816) 39,270 Stock Based Compensation 3,590,473 812,073 Changes in Operating Assets & Liabilities (net of Acquired Amounts): Accounts Receivable 927,259 (105,185) Inventory 4,571,069 789,399 Prepaid Expenses & Other Current Assets 1,579,349 (2,770,179) Other Assets 263,419 (248,682) Change in Operating Lease Liabilities (7,498,128) (13,113,041) Accounts Payable & Other Liabilities (3,241,850) 11,845,245 Income Taxes Payable 17,934,967 5,270,074 Net Cash Provided by (Used in) Operating Activities 12,200,963 6,694,346 Cash Flows from Investing Activities: Collection of Notes Receivable 11,944 Cash Consideration for Acquisition of Business, net of Cash Acquired (15,834,378) (58,981,226) Purchase of Fixed Assets (7,865,654) (14,007,892) Purchase of Intangible Assets (2,750,000) Investment in Private Entity (2,000,000) Net Cash Provided by (Used in) Investing Activities (26,438,088) (74,989,118) Cash Flows from Financing Activities: Payment on Notes Payable (5,354,218) (134,498) Proceeds from Issuance of Common Stock 978,308 Payment for Statutory Withholdings on RSU (108,978) Net Cash Provided by (Used in) Financing Activities (5,463,196) 843,810 Net (Decrease) in Cash & Cash Equivalents (19,700,321) (67,450,962) Cash & Cash Equivalents at Beginning of Period 38,949,253 106,400,216 Cash & Cash Equivalents at End of Period $ 19,248,932 $ 38,949,253 Supplemental Disclosure of Cash Flow Information: Cash Paid for Interest $ 17,896,954 $ 15,243,990 Cash Paid for Income Taxes 5,000,000 12,340,000
MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars
For the Three Months Ended For the Twelve Months Ended December 31, December 31, 2023 2022 2023 2022 Net Income (Loss) $ (29,364,680) $ (27,339,133) $ (34,549,344) $ (18,467,615) Interest Expense, net 8,112,391 6,827,557 32,069,082 30,139,645 Provision for Income Taxes 4,494,049 3,638,695 19,740,595 14,898,064 Other (Income) Expense, net of Interest Expense 516,180 14,367,747 (13,971,641) (13,715,260) Depreciation & Amortization 3,162,425 3,701,128 18,970,960 12,524,677 Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (non-GAAP) $ (13,079,635) $ 1,195,994 $ 22,259,652 $ 25,379,511 Non-Cash Stock Compensation 1,597,157 883,890 2,219,319 2,672,713 Deal Related Expenses 2,196,733 1,914,820 5,528,048 6,822,111 Capital Raise Related Expenses 1,779 (257,271) 38,559 533,958 Inventory Adjustment to Fair Market Value for Purchase Accounting 5,792,488 5,792,488 6,541,651 One-Time Inventory Impairment 7,353,972 7,353,972 One-Time Goodwill Impairment 1,801,740 8,011,405 1,801,740 8,011,405 Severance 111,752 263,374 537,584 334,910 Retention Program Expenses 505,655 Employee Relocation Expenses 5,065 (3,750) 70,107 15,360 Pre-Operating & Dark Carry Expenses 2,663,824 1,027,738 2,663,824 1,027,738 One-Time Legal Settlements 1,204,058 440,000 1,204,058 440,000 Other Non-Recurring Items 1,304,501 (191,674) 3,436,773 230,858 Adjusted EBITDA (non-GAAP) $ 10,953,434 $ 13,284,526 $ 53,411,779 $ 52,010,215 Revenue 43,324,815 40,147,287 172,447,786 159,379,219 Adjusted EBITDA Percent 25.3 % 33.1 % 31.0 % 32.6 %
View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-fourth-quarter-and-full-year-2023-financial-results-302101678.html [https://www.prnewswire.co.uk/news-releases/schwazze-announces-fourth-quarter-and-full-year-2023-financial-results-302101678.html]
Schwazze